Towards this end, we analyzed the mRNA expression levels of AREG and EREG, two EGFR ligands that are mitogenic stimulators, promoting tumor growth and survival by autocrine/paracrine loop mechanism and are known to impact response to cetuximab in CRC patients in conjunction with KRAS mutation status21, 28. This evidence concerns the gene KRAS and neoplasm.